Plain-English translation of NCT07363551 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This 12-week study is testing whether EPA, an omega-3 fatty acid found in fish oil, can help reduce depression symptoms in young people. Researchers will track changes in mood, inflammation markers in the blood, and the healthy bacteria in your gut to understand how the medication might work. Half of participants will receive the actual omega-3 treatment, and half will receive a placebo (a harmless substitute that looks identical).
Depression is a serious condition that doesn't always respond well to current treatments alone. Recent research suggests that inflammation and gut health may play a role in depression, so scientists want to see if this medication—which has anti-inflammatory properties—could offer a new way to help young people feel better.
You likely qualify if…
You likely don't qualify if…
You will take a daily pill (either the active omega-3 supplement or placebo) for 12 weeks. You'll visit the research clinic at the start, during the middle, and at the end of the study for check-ins where researchers will ask about your mood, draw blood to measure inflammation, and possibly collect a stool sample to check your gut bacteria. The whole commitment is about 12 weeks.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
Taiwan
Enrollment target
~60 participants
Started
June 2021
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
13 Years – 18 Years
Last updated on clinicaltrials.gov in January 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.